do you have any numbers of your own for this matter? It would be a privilege to be able to compare them.Again with all due respect I assume you would be taking a much lesser stance .Apologies if this is incorrect
Printable View
do you have any numbers of your own for this matter? It would be a privilege to be able to compare them.Again with all due respect I assume you would be taking a much lesser stance .Apologies if this is incorrect
I’d like to offer a balancing view paper tiger if I may for thought and discussion, we all have differing risk appetites after all.
PEB seem to me to be de-risking steadily, first sales achieved, regulatory approvals in place, laboratories constructed on budget/schedule, trials achieved with DHB’s and prospectively now with US counterparts, technology risk is dropping away as those trials in application provide better than anticipated results.
Yes, there are still risks yet to be concluded and some that will be on-going as for all businesses, competitors exist although none are anywhere close to being market ready, saleability and price point, ability to break existing NMP22 technology entrenchment and loyalties.
The only significant difficulty I personally have is not having direct access to good market data so it’s hard to self-assess, but this seems to be an industry issue, health professionals don’t give much away, it’s a patient confidentially culture.
The sales strategy that PEB has revealed seems to be intelligent and comprehensive as does the market research provided by them.
My view is that the projected sales and $100M revenue curve is looking more and more achievable and attractive every day that goes by.
My present fully de-risked valuation on that revenue stream is $1.25
It may now just take one good US contract announcement and a five year uptrend may commence.
for those watching this debate with Paper Tiger the posts in question are peb 654 through 661
This fascinates me, it appears we are on the cusp of good sales in the US and NZ, yet the market response is to sell!
I am guessing that not many people read the NBR article then?
It is interesting blobbles. It seemed that what we saw last week was a strategic breakdown of technical levels on no news, also we’ve seen sell downs at the close each day this week. Could well be a large player forcing the market down for a better entry point, just because they can. Still it's just short term noise, with fundamentals like these a positive announcement will turn matters around real quick.
Crumbs, I hope you picked a few of those up at the time Hancock’s, they’re only up 110% ?.
There's not actually been a lot of volume in the selling in the last few days, no disclosures, not much on the morningstar site either.
http://investors.morningstar.com/own...&culture=en-US
still silly old them
Attachment 4769
Best Wishes
Paper Tiger
Below job add posted today - note highlighted new products " state of the art cancer management products". Seems a natural progression from the diagnostic tools - not sure if this has been disclosed before (surprised if it hasn't).
Ref /Job ID: 88386796438C02E7 / 5952385 Industry: Science, Technology, R&D, Biotech Company:Pacific Edge Limited Location:Australia Australia 0 - 0 Type: Full Time Advertiser: Agency Posted: 31-08-2013 Closing: 07-09-2013
Pacific Edge Limited is a Dunedin-based biomedical company specialisingin the development and commercialisation of diagnostics and prognostics for arange of cancers including bladder, colorectal and gastric. The Company hascompleted a successful international multicenter clinical trial for its bladdercancer detection test Cxbladder. The Company’s colorectal cancer prognosticgene signature has also recently successfully completed its clinical trial inEurope. Pacific Edge Limited has nowmoved to commercialise these products into global markets. As part of ourdevelopment and growth strategy Pacific Edge Limited has formed aninternational network of collaborations and alliances with research institutesand companies in Australasia, North America, Europe and Asia. The Company isnow seeking to appoint a top-level scientist who will be considered critical indeveloping and implementing the Company’s clinical program for moleculardiagnostic testing and contribute to thevision of developing state of the art cancer management products. Thesuccessful candidate will join a commercial, product-focused team in anenvironment where communication and collaboration are essential. You will beinvolved in all facets of the clinical program development including buildingline extensions to existing products, implementation of product pipelines andevaluating novel molecular diagnostics tests in a commercial laboratorysetting. Specifically applicants will have: • PhD in a relevant sciencediscipline with a minimum of 4 years post doctoral experience • Proven abilityto plan, execute and report scientific clinical studies • Experience with therunning of human clinical trials • A knowledge of or strong interest inclinical diagnostics • Ability to communicate fluently verbally and in writingto a wide variety of stakeholders, including physicians • Ability to performwell as a member of a team as well as showing leadership in areas of primaryresponsibility • Flexible can-do attitude • A willingness and aptitude to help turnscientific ideas into commercial reality. It would be advantageous forapplicants to have: • A knowledge of the regulatory environment for clinicallaboratories • Experience with bio resource collections (Bio Banks) We areoffering an exciting and challenging job with a competitive salary commensuratewith experience and skills. Pacific Edge Limited is based in Dunedin in closeproximity to the University of Otago and the successful candidate will beworking with a professional team in a great working environment.
Perhaps someone from the health sector can assist ?
At the AGM David Darling advised that PEB are presently selling in the US at a price point of $550 per test, and I’m still trying to interpret what this actually means. This is at the lower end of the 2011 capital raising guidance of $550 to $630.
A common sales and marketing strategy is to offer ‘trials’ at a lower price, once both parties are satisfied with the results, sales may continue at a normal (higher) price point, let’s say $630 per test.
Or, is this not a customary sales practice in the health sector ?
So we may also have some sort of a wholesale / retail thing going on also ?. I guess that may mean that direct sales to the US insurers may then come at a higher price point.
I'm actually very encouraged that PEB are presently "in discussion" with their first US customer, the fact that PEB are prepared to publicly declare this suggests they are confident it will indeed happen. And, being roughly three times the size of all NZ DHB’s combined, well need we say more.
I'm increasingly becoming more bullish, it seems that after years of kicking around the lab we are at the tipping point of sales exploding now.
Even just having a few LUG's under trial would represent huge sales volumes.
Don't wait too long baller... not sure how long it will be before the general public realise they are on the cusp of big sales. Hopefully a bit longer (and the price falls a bit more!) so I can top up at stupid prices too!
There was continued selling on the close Friday, this time with a 500k parcel lobbed out.
probably the same seller we have seen all week. Watch the open and close to see if they are still exiting in 50, 100, and now 500k parcels
my concern is it must be one of the larger holders (who still lobbed out after the NBR reported comments) What do they know?, but then what do I know, lol
the 60 cent capper has come down to market I suspect, but it's only conjecture on my part.
would that buyer of 333,333 the other week like to step up for another 555,555. Lucky for some.....
Two good unreliable indicators of stock market probability this morning, much more light and agricultural aircraft traffic recently and hemlines are definitely on the rise.:)